◊ Amgen News Today ◊
♦ Amgen Buy Otezla ♦ Stock Market News ♦ … — Amgen Inc. said it has agreed to buy Celgene Corp. ’s psoriasis treatment Otezla for $13.4 billion in cash, in a deal that would pave the way for Bristol-Myers Squibb Co. to complete its acquisition of Celgene. Amgen said Monday the deal is worth about $11.2 billion, net of anticipated future cash tax benefits.
Bristol-Myers in January said it would acquire Celgene in a deal valued at about $74 billion, but the U.S. Federal Trade Commission raised anticompetitive concerns related to anti-inflammatory drugs. In June, the companies said they would shed Otezla to satisfy the FTC’s concerns.
Bristol-Myers on Monday said the sale of Otezla to Amgen is contingent on a consent decree with the FTC and completion of the Celgene acquisition, which the company now expects to occur by the end of the year.
Amgen, a Thousand Oaks, Calif., biotechnology company, said Otezla is a strong strategic fit with its psoriasis and inflammation portfolio and it expects at least low-double-digit sales growth for the drug, on average, over the next five years.
Shares of Bristol-Myers rose 4.2% in morning trading. Celgene shares added 3.7% and Amgen climbed 2.1%. Amgen, which has been pressured recently by the introduction of copycats to its white blood cell booster Neulasta and calcium reducer Sensipar, saidOtezla has exclusivity through at least 2028 in the U.S.
>>> Online Loans Up To $5,000 <<<
>>> Online Loans Up To $5,000 <<<
Bristol-Myers said it would use proceeds from the Otezla sale to pare its debt load, adding that it plans to focus on deleveraging in the near term to maintain strong investment-grade credit ratings and a ratio of debt to earnings before interest, taxes, depreciation and amortization of below 1.5-times by 2023.
The New York drugmaker also raised an accelerated share repurchase program, planned for after the Celgene deal closes, to $7 billion from $5 billion.
- Trump on Trade War: China Wants To Negotiate…
- Financial Markets: Top 5 Things to Watch This Week
- G7: The Summit in France Comes Amid Fears Over a Global Economic Slowdown
- Trump Will Hike Tariff Rates on Most Imports From China
- Home Depot Cuts Sales Forecast
- Kraft Heinz Shares Fall 15 Percent
- Berkshire Hathaway Posts Rising Profit
- Pfizer Agreed To Merge Its Off-Patent Drugs Business With Mylan
Amgen Inc Company Profile:
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment.
Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.